Title:Effective on March 3, 2019, Tri-Service General Hospital (TSGH) became the first medical center in Taiwan approved by Ministry of Health and Welfare (MOHW) to perform cellular therapies on patients.Published day:2019/5/3
Tri-Service General Hospital (TSGH) has submitted its autologous immune cell (CIK) treatment plan for hematological cancer patients who failed standard treatment for MOHW’s review and approval as early as in October, 2018, per “Administrative Measures for the Implementation or Use of Specific Medical Technology and Inspection, Diagnostic or Medical Devices” promulgated by Ministry of Health and Welfare (MOHW). As part of its cellular treatment plan submission, TSGH has task-organized a treatment group consisted of specialists of cellular therapy primarily from Division of Hematology & Oncology, TSGH. From blood samples collected from patients to lab procedures of ensuring immune cell cytotoxicity and tumor growth and quantity increase, to final steps of delivering cellular treatment products back to TSGH in optimally aseptic storage condition, TSGH treatment group team members, in partnership with industry partners, will employ the highest lab and clinical standards to ensure patient safety and clinical outcome for patients receiving treatment. TSGH medical team and its industry partner lab will make every effort to ensure that each and every procedure involved in its cellular therapy center is performed under stringent professional oversight and high-level monitoring, aimed at providing state-of-the-art cellular treatment options for eligible patients and their families.
At present, the treatment technology has been adopted and applied to patients with hematological malignancies (ineffective by standard treatment or in terminal stage), malignant lymphoma, Waldenstrom's macroglobulinemia, and multiple myeloma. TSGH’s cellular therapy program will soon also apply to patients in the fourth stage of liver cancer and lung cancer, allowing for more treatment options and services for cancer patients.